Chief Medical Officer William Savage of Disc Medicine Inc (IRON, Financial) sold 1,500 shares of the company on September 16, 2024, according to a recent SEC Filing. The transaction occurred at a price of $47.41 per share, totaling $71,115. Following this transaction, the insider now owns 40,405 shares of the company.
Disc Medicine Inc is engaged in the development of treatments for serious and debilitating hematologic diseases. The company focuses on addressing unmet medical needs in the field of hematology.
Over the past year, William Savage has sold a total of 3,000 shares of Disc Medicine Inc and has not purchased any shares. This recent sale represents a continuation of the insider's selling trend.
The insider transaction history for Disc Medicine Inc shows a pattern of more insider sales than buys over the past year, with 27 insider sells and only 3 insider buys. This could be indicative of the insider’s sentiment towards the stock’s current valuation and future prospects.
Shares of Disc Medicine Inc were trading at $47.41 on the day of the transaction, giving the company a market cap of approximately $1.416 billion. This valuation aligns with the GF Value, which is a proprietary measure used to determine the fair value of a stock.
The stock’s valuation metrics include a price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, which investors often use to assess the stock's relative valuation in the market.
This insider sale might be of interest to current and potential investors trying to understand market sentiment and the actions of company insiders. Such transactions can provide insights into how insiders view the stock's current valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
